Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide added to infliximab for moderate-to-severe hidradenitis suppurativa
IRCT20230502058057N2Phase 2Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tirzepatide and infliximab in hidradenitis suppurativa (HS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Achievement of Hidradenitis Suppurativa Clinical Response at week 24. Started Oct 2026; status: recruiting.
02
Drugs
tirzepatideinfliximab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on IRCT20230502058057N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230502058057N2.